Ex vivo model for studying endothelial tip cells: Revisiting the classical aortic-ring assay

A drug undergoes several in silico, in vitro, ex vivo and in vivo assays before entering into the clinical trials. In 2014, it was reported that only 32% of drugs are likely to make it to Phase-3 trials, and overall, only one in 10 drugs makes it to the market. Therefore, enhancing the precision of...

Full description

Saved in:
Bibliographic Details
Published in:Microvascular research 2020-03, Vol.128, p.103939-103939, Article 103939
Main Authors: Katakia, Yash T., Duddu, Sushmitha, S., Nithya, Kumar, Pavitra, Rahman, Farhana, Kumaramanickavel, Govindasamy, Chatterjee, Suvro
Format: Article
Language:English
Subjects:
Chick aortic ring assay
Drug testing
Endothelium
Human placenta ex-plant
Sprouting angiogenesis
Tip cell
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A drug undergoes several in silico, in vitro, ex vivo and in vivo assays before entering into the clinical trials. In 2014, it was reported that only 32% of drugs are likely to make it to Phase-3 trials, and overall, only one in 10 drugs makes it to the market. Therefore, enhancing the precision of pre-clinical trial models could reduce the number of failed clinical trials and eventually time and financial burden in health sciences. In order to attempt the above, in the present study, we have shown that aortic ex-plants isolated from different stages of chick embryo and different regions of the aorta (pulmonary and systemic) have differential sprouting potential and response to angiogenesis modulatory drugs. Aorta isolated from HH37 staged chick embryo showed 16% (p 
ISSN:0026-2862
1095-9319
DOI:10.1016/j.mvr.2019.103939